Acquisition History / Shionogi & Co. / Torii Pharmaceutical and JT pharmaceutical business

Shionogi & Co. Acquires Torii Pharmaceutical and JT pharmaceutical business

Announced May 7, 2025 — $1.10B

Shionogi & Co.Pharmaceuticals2025

What happened

Torii Pharmaceutical is a Tokyo-listed drugmaker majority-owned by Japan Tobacco. Shionogi announced it would acquire Torii and other JT pharmaceutical assets in a deal worth around ¥160B, amid consolidation driven by rising R&D costs.

Acquirer
Shionogi & Co.
Target
Torii Pharmaceutical and JT pharmaceutical business
Announced
May 7, 2025
Price
$1.10B
Industry
Pharmaceuticals
Buyer type
Strategic acquirer
Status
Announced, not yet closed

By the numbers

Shionogi & Co.'s acquisition history
1st of 1 tracked deals
Disclosed prices
1 of 1 Shionogi & Co. deals
Shionogi & Co.'s average disclosed price
$1.10B
Shionogi & Co.'s largest disclosed deal
Torii Pharmaceutical and JT pharmaceutical business ($1.10B)
Tracked acquisitions in 2025
503 across all acquirers
Shionogi & Co. in Pharmaceuticals
1 acquisition

Frequently Asked Questions About This Acquisition

When did Shionogi & Co. acquire Torii Pharmaceutical and JT pharmaceutical business?

Shionogi & Co. acquired Torii Pharmaceutical and JT pharmaceutical business on May 7, 2025. This was Shionogi & Co.'s 1st publicly tracked acquisition out of 1 we have on record.

How much did Shionogi & Co. pay for Torii Pharmaceutical and JT pharmaceutical business?

Shionogi & Co. paid $1.10B for Torii Pharmaceutical and JT pharmaceutical business.

What does Torii Pharmaceutical and JT pharmaceutical business do?

Torii Pharmaceutical is a Tokyo-listed drugmaker majority-owned by Japan Tobacco. Shionogi announced it would acquire Torii and other JT pharmaceutical assets in a deal worth around ¥160B, amid consolidation driven by rising R&D costs.

What other Pharmaceuticals companies has Shionogi & Co. acquired?

Torii Pharmaceutical and JT pharmaceutical business is Shionogi & Co.'s only publicly tracked acquisition in Pharmaceuticals so far.

Read the full article →

More Pharmaceuticals acquisitions